MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

Jodi Haartsen; S. Agland; J Baker; T Burke; L Rath; Jeannette Lechner-Scott; B Taylor; Steve Vucic; M Barnett; Mark Slee; S. Hodgkinson; Olga Skibina; Allan Kermode; E. Butler; Neil Shuey; C Shaw; Tristan Hardy; I. L. Tan; H Butzkueven; Tim Spelman; MS FIRST Study Group

doi:10.1177/1352458515602640

MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

Jodi Haartsen, S. Agland, J Baker, T Burke, L Rath, Jeannette Lechner-Scott, B Taylor, Steve Vucic, M Barnett, Mark Slee, S. Hodgkinson, Olga Skibina, Allan Kermode, E. Butler, Neil Shuey, C Shaw, Tristan Hardy, I. L. Tan, H Butzkueven, Tim SpelmanMS FIRST Study Group

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	18-19
Number of pages	2
Journal	Multiple Sclerosis
Volume	21
Issue number	Supp: 11
DOIs	https://doi.org/10.1177/1352458515602640
Publication status	Published - Sept 2015
Event	31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis - Barcelona, Spain Duration: 7 Oct 2015 → 10 Oct 2015 Conference number: 31

Access to Document

10.1177/1352458515602640Licence: In Copyright

Cite this

Haartsen, J., Agland, S., Baker, J., Burke, T., Rath, L., Lechner-Scott, J., Taylor, B., Vucic, S., Barnett, M., Slee, M., Hodgkinson, S., Skibina, O., Kermode, A., Butler, E., Shuey, N., Shaw, C., Hardy, T., Tan, I. L., Butzkueven, H., ... MS FIRST Study Group (2015). MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events. Multiple Sclerosis, 21(Supp: 11), 18-19. https://doi.org/10.1177/1352458515602640

@article{d4c559b6a16c403187d181f5fbb81f2f,

title = "MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events",

author = "Jodi Haartsen and S. Agland and J Baker and T Burke and L Rath and Jeannette Lechner-Scott and B Taylor and Steve Vucic and M Barnett and Mark Slee and S. Hodgkinson and Olga Skibina and Allan Kermode and E. Butler and Neil Shuey and C Shaw and Tristan Hardy and Tan, {I. L.} and H Butzkueven and Tim Spelman and {MS FIRST Study Group}",

year = "2015",

month = sep,

doi = "10.1177/1352458515602640",

language = "English",

volume = "21",

pages = "18--19",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "Supp: 11",

note = "31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, ECTRIMS ; Conference date: 07-10-2015 Through 10-10-2015",

}

Haartsen, J, Agland, S, Baker, J, Burke, T, Rath, L, Lechner-Scott, J, Taylor, B, Vucic, S, Barnett, M, Slee, M, Hodgkinson, S, Skibina, O, Kermode, A, Butler, E, Shuey, N, Shaw, C, Hardy, T, Tan, IL, Butzkueven, H, Spelman, T & MS FIRST Study Group 2015, 'MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events', Multiple Sclerosis, vol. 21, no. Supp: 11, pp. 18-19. https://doi.org/10.1177/1352458515602640

MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events. / Haartsen, Jodi; Agland, S.; Baker, J et al.
In: Multiple Sclerosis, Vol. 21, No. Supp: 11, 09.2015, p. 18-19.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

AU - Haartsen, Jodi

AU - Agland, S.

AU - Baker, J

AU - Burke, T

AU - Rath, L

AU - Lechner-Scott, Jeannette

AU - Taylor, B

AU - Vucic, Steve

AU - Barnett, M

AU - Slee, Mark

AU - Hodgkinson, S.

AU - Skibina, Olga

AU - Kermode, Allan

AU - Butler, E.

AU - Shuey, Neil

AU - Shaw, C

AU - Hardy, Tristan

AU - Tan, I. L.

AU - Butzkueven, H

AU - Spelman, Tim

AU - MS FIRST Study Group

N1 - Conference code: 31

PY - 2015/9

Y1 - 2015/9

UR - http://journals.sagepub.com/doi/pdf/10.1177/1352458515602640

U2 - 10.1177/1352458515602640

DO - 10.1177/1352458515602640

M3 - Meeting Abstract

SN - 1352-4585

VL - 21

SP - 18

EP - 19

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - Supp: 11

T2 - 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Y2 - 7 October 2015 through 10 October 2015

ER -

Haartsen J, Agland S, Baker J, Burke T, Rath L, Lechner-Scott J et al. MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events. Multiple Sclerosis. 2015 Sept;21(Supp: 11):18-19. doi: 10.1177/1352458515602640

MS FIRST - utilising a drug safety module for use in MS clinical practice to evaluate lymphocyte reduction in fingolimod treatment over time, demographic predictors of lymphopenia and association with reported safety events

Access to Document

Other files and links

Cite this